IL139400A0 - Long-acting cytokine derivatives and pharmaceutical compositions comprising them - Google Patents

Long-acting cytokine derivatives and pharmaceutical compositions comprising them

Info

Publication number
IL139400A0
IL139400A0 IL13940000A IL13940000A IL139400A0 IL 139400 A0 IL139400 A0 IL 139400A0 IL 13940000 A IL13940000 A IL 13940000A IL 13940000 A IL13940000 A IL 13940000A IL 139400 A0 IL139400 A0 IL 139400A0
Authority
IL
Israel
Prior art keywords
cytokine
pharmaceutical compositions
derivatives
fluorenylmethoxycarbonyl
fms
Prior art date
Application number
IL13940000A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL13940000A priority Critical patent/IL139400A0/xx
Priority to PCT/IL2001/001005 priority patent/WO2002036067A2/fr
Priority to DE60134883T priority patent/DE60134883D1/de
Priority to AU2002214223A priority patent/AU2002214223A1/en
Priority to IL15565601A priority patent/IL155656A0/xx
Priority to EP01982682A priority patent/EP1337270B1/fr
Priority to AT01982682T priority patent/ATE401098T1/de
Publication of IL139400A0 publication Critical patent/IL139400A0/xx
Priority to IL155656A priority patent/IL155656A/en
Priority to US10/415,668 priority patent/US20040131586A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL13940000A 2000-11-01 2000-11-01 Long-acting cytokine derivatives and pharmaceutical compositions comprising them IL139400A0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL13940000A IL139400A0 (en) 2000-11-01 2000-11-01 Long-acting cytokine derivatives and pharmaceutical compositions comprising them
PCT/IL2001/001005 WO2002036067A2 (fr) 2000-11-01 2001-10-30 Derives de cytokine de longue action et compositions pharmaceutiques comprenant ces derives
DE60134883T DE60134883D1 (de) 2000-11-01 2001-10-30 Interferon- und interleukin-derivate mit langzeitwirkung und diese enthaltende pharmazeutische zusammensetzungen
AU2002214223A AU2002214223A1 (en) 2000-11-01 2001-10-30 Long-acting cytokine derivatives and pharmaceutical compositions comprising them
IL15565601A IL155656A0 (en) 2000-11-01 2001-10-30 Long-acting cytokine derivatives and pharmaceutical compositions comprising them
EP01982682A EP1337270B1 (fr) 2000-11-01 2001-10-30 Derives d'interferon et d'interleukine de longue action et compositions pharmaceutiques comprenant ces derives
AT01982682T ATE401098T1 (de) 2000-11-01 2001-10-30 Interferon- und interleukin-derivate mit langzeitwirkung und diese enthaltende pharmazeutische zusammensetzungen
IL155656A IL155656A (en) 2000-11-01 2003-04-29 History of interferon and interleukin have continuous activity and pharmaceutical preparations containing them
US10/415,668 US20040131586A1 (en) 2000-11-01 2003-09-02 Long-acting cytokine derivatives and pharmaceutical compositions comprising them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13940000A IL139400A0 (en) 2000-11-01 2000-11-01 Long-acting cytokine derivatives and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
IL139400A0 true IL139400A0 (en) 2001-11-25

Family

ID=11074784

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13940000A IL139400A0 (en) 2000-11-01 2000-11-01 Long-acting cytokine derivatives and pharmaceutical compositions comprising them
IL155656A IL155656A (en) 2000-11-01 2003-04-29 History of interferon and interleukin have continuous activity and pharmaceutical preparations containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155656A IL155656A (en) 2000-11-01 2003-04-29 History of interferon and interleukin have continuous activity and pharmaceutical preparations containing them

Country Status (7)

Country Link
US (1) US20040131586A1 (fr)
EP (1) EP1337270B1 (fr)
AT (1) ATE401098T1 (fr)
AU (1) AU2002214223A1 (fr)
DE (1) DE60134883D1 (fr)
IL (2) IL139400A0 (fr)
WO (1) WO2002036067A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2521784C (fr) * 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Medicaments pegyles reversibles
BRPI0611872B8 (pt) * 2005-06-16 2021-05-25 Nektar Therapeutics reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
WO2011013128A2 (fr) 2009-07-31 2011-02-03 Yeda Research And Development Co. Ltd. Vecteurs destinés à l'administration de neurothérapies au système nerveux central
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
MX362432B (es) 2012-06-04 2019-01-17 Opko Biologics Ltd Variantes de oxm pegilada.
CN106554296A (zh) * 2015-09-30 2017-04-05 深圳翰宇药业股份有限公司 一种具有良好亲水性的Fmoc（SO3H）保护的氨基酸及其制备方法
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
CN117551008B (zh) * 2023-11-10 2025-10-17 沈阳药科大学 一种去铁胺偶联物及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them

Also Published As

Publication number Publication date
EP1337270A2 (fr) 2003-08-27
WO2002036067A2 (fr) 2002-05-10
IL155656A (en) 2010-02-17
DE60134883D1 (de) 2008-08-28
ATE401098T1 (de) 2008-08-15
EP1337270B1 (fr) 2008-07-16
EP1337270A4 (fr) 2005-09-14
US20040131586A1 (en) 2004-07-08
AU2002214223A1 (en) 2002-05-15
WO2002036067A3 (fr) 2003-01-09

Similar Documents

Publication Publication Date Title
AP1760A (en) Platinum derivative pharmaceutical formulations.
SI0991407T1 (en) Stabilization of acid sensitive benzimidazols with amino/cyclodextrin combinations
GR3026218T3 (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro derivatives of alpha D-neuraminic acid
EP0696208A4 (fr) Compositions et procedes d'administration de medicaments par voie orale
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
FI863889A0 (fi) Farmaceutisk produkt som laongsamt friger aktivt aemne.
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
WO2000045800A3 (fr) Effets immunosuppresseurs des derives de pteridine
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
IL139400A0 (en) Long-acting cytokine derivatives and pharmaceutical compositions comprising them
HUP0102369A3 (en) Amino acid derivatives and drugs containing the same as the active ingredient
IT1284604B1 (it) Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
WO1999012545A3 (fr) Medicaments contenant acyclovir
CA2386423A1 (fr) Compositions pharmaceutiques et leur utilisation
AU3739500A (en) Protease resistant flint analogs
DE69813263T2 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
RU94040865A (ru) Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью
HUP0004362A2 (hu) Karbamazepint vagy származékait tartalmazó parenterális készítmények
ITMI20020872A1 (it) Derivati dell'iperforina loro uso e formulazioni che li contengono
WO1993018059A3 (fr) Derive d'acide l-thiazolidine-4-carboxylique, ses procedes de preparation et son utilisation en therapie
ATE252598T1 (de) Streptograminderivate, ihre herstellung und sie enthaltende zubereitungen
UA64074C2 (uk) Кардіопротекторний антиоксидантний засіб "елгацин"
MY152490A (en) New oral formulation